Skip to content
BOE-A-2026-3215 ·12 February 2026 ·Royal Decree Medium impact
Tax

Pharmaceutical companies: 1 July deadline to adapt selective funding procedures or lose SNSS coverage rights

Royal Decree 90/2026 repeals Order SCO/470/2002 and Royal Decree 9/1996, establishing a new selective funding procedure for medical devices covered by the SNSS pharmaceutical benefit. Procedures must be adapted before 1 July 2026; otherwise, the right to selective funding will be lost (Art. 1, final provision 6.2).

In 2 key points

  1. Order SCO/470/2002 and Royal Decree 9/1996 are repealed (art. 1)
  2. Selective funding procedures must be adapted before 1 July 2026 (disp. final 6.2)

How it affects those involved

Pharmaceutical companies distributing medical devices for non-hospitalised patients must update their procedures before 1 July 2026 to avoid losing selective funding rights. Health advisors and pharmaceutical managers must review submission and compliance processes. Health authorities may apply the new regime from that date, without retroactivity.

Lifecycle

2026-02-12PublishedPublished in the BOE
2026-07-01Into forceComes into force (fecha_vigencia (indice oficial del BOE))
Official text Based on BOE data (boe.es). Information, not advice.

Does this provision affect you?

The tax team reviews your specific situation.

Talk to the tax team
This analysis is informational only and does not constitute legal advice or create a client-adviser relationship. BM Consulting.
Email
Contact